AbbVie Inc. is 277.9x more valuable than KalVista Pharmaceuticals, Inc. by market capitalization ($399.47 B vs $1.44 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | KALV | ABBV |
|---|---|---|
| Market cap | $1.44 B | $399.47 B |
| US-listed rank | #2361 | #28 |
| Revenue (latest FY) | $50.00M | $61.16B |
| Net income (latest FY) | -$183.40M | $4.23B |
| Net margin | -366.8% | 6.9% |
| P/E (trailing FY) | - | 94.5 |
| SEC filings | 834 | 1,008 |
AbbVie Inc. is 277.9x more valuable than KalVista Pharmaceuticals, Inc. by market capitalization ($399.47 B vs $1.44 B).
In their latest fiscal years, KalVista Pharmaceuticals, Inc. reported $50.00M in revenue while AbbVie Inc. reported $61.16B.
Full pages: KalVista Pharmaceuticals, Inc. and AbbVie Inc., or browse the full rankings.